Canada - English - Health Canada

mint pharmaceuticals inc - ursodiol - tablet - 500mg - ursodiol 500mg - cholelitholytic agents

United States - English - NLM (National Library of Medicine)

kvk-tech, inc. - ursadiol (unii: 3d089v7l0k) (ursadiol - unii:3d089v7l0k) - - ursodiol capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of ursodiol capsules beyond 24 months is not established. - ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - ursodiol capsules will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. hence, patients with such stones are not candidates for ursodiol capsules therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol capsules therapy. - allergy to bile aci

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ursadiol (unii: 3d089v7l0k) (ursadiol - unii:3d089v7l0k) - - ursodiol capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of ursodiol capsules beyond 24 months is not established. - ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - ursodiol capsules will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. hence, patients with such stones are not candidates for ursodiol capsules therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol capsules therapy. - allergy to bile aci

United States - English - NLM (National Library of Medicine)

professional group of pharmacists new york llc - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) -

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol 300 mg - - actigall is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of actigall beyond 24 months is not established. - actigall is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - actigall will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment  stones. hence, patients with such stones are not candidates for actigall therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for actigall therapy. - allergy to bile acids.

United States - English - NLM (National Library of Medicine)

allergan, inc. - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol 300 mg - - actigall is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of actigall beyond 24 months is not established. - actigall is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - actigall will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. hence, patients with such stones are not candidates for actigall therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for actigall therapy. - allergy to bile acids.

United States - English - NLM (National Library of Medicine)

kalchem international inc - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) -

United States - English - NLM (National Library of Medicine)

evereen shanghai biotechnology ltd. - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol 24.75 kg in 25 kg

United States - English - NLM (National Library of Medicine)

cardinal health - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol 250 mg